Any salt or ester of glycerophosphoric acid.

Purinogen is not an endogenous substrate used in endothelial cells during substrate deprivation. (1/754)

Porcine aortic endothelial cells (PAEC) are known to be metabolically robust. They are capable of surviving extended periods of complete lack of exogenous substrate, and purine release has been shown to be significantly up-regulated. The endogenous substrates used during substrate deprivation, as well as the sources responsible for the increased purine release, have not been completely identified. We tested the possibility that a phosphoglyceroyl-ATP-containing polymer, purinogen, might support PAEC hibernation induced by lack of exogenous substrate. This involved isolation of the acid-insoluble fraction of PAEC, which was presumed to contain purinogen, and analysis by HPLC and 31P NMR. No evidence supporting the presence of triphosphate-containing compounds (purinogen) was found. Similar results were obtained in the rat heart. The majority of the products in the acid-insoluble, alkaline-treated fraction were identified as RNA degradation products (2'- and 3'-nucleoside monophosphates). A [14C]adenosine labelling experiment showed that incorporation of adenosine into the acid-insoluble fraction was almost completely prevented after inhibition of RNA synthesis with actinomycin D. Furthermore, RNA isolated from PAEC and subsequently treated with alkali showed a profile that was almost identical with the HPLC profile of the acid-insoluble fraction. Finally, substrate-free incubation of the cells did not quantitatively or qualitatively influence the distribution of acid-insoluble derivatives. We conclude that PAEC survival during the absence of exogenous substrate is not supported by purinogen but rather by some other, yet-to-be-identified, endogenous substrate.  (+info)

Redundant systems of phosphatidic acid biosynthesis via acylation of glycerol-3-phosphate or dihydroxyacetone phosphate in the yeast Saccharomyces cerevisiae. (2/754)

In the yeast Saccharomyces cerevisiae lipid particles harbor two acyltransferases, Gat1p and Slc1p, which catalyze subsequent steps of acylation required for the formation of phosphatidic acid. Both enzymes are also components of the endoplasmic reticulum, but this compartment contains additional acyltransferase(s) involved in the biosynthesis of phosphatidic acid (K. Athenstaedt and G. Daum, J. Bacteriol. 179:7611-7616, 1997). Using the gat1 mutant strain TTA1, we show here that Gat1p present in both subcellular fractions accepts glycerol-3-phosphate and dihydroxyacetone phosphate as a substrate. Similarly, the additional acyltransferase(s) present in the endoplasmic reticulum can acylate both precursors. In contrast, yeast mitochondria harbor an enzyme(s) that significantly prefers dihydroxyacetone phosphate as a substrate for acylation, suggesting that at least one additional independent acyltransferase is present in this organelle. Surprisingly, enzymatic activity of 1-acyldihydroxyacetone phosphate reductase, which is required for the conversion of 1-acyldihydroxyacetone phosphate to 1-acylglycerol-3-phosphate (lysophosphatidic acid), is detectable only in lipid particles and the endoplasmic reticulum and not in mitochondria. In vivo labeling of wild-type cells with [2-3H, U-14C]glycerol revealed that both glycerol-3-phosphate and dihydroxyacetone phosphate can be incorporated as a backbone of glycerolipids. In the gat1 mutant and the 1-acylglycerol-3-phosphate acyltransferase slc1 mutant, the dihydroxyacetone phosphate pathway of phosphatidic acid biosynthesis is slightly preferred as compared to the wild type. Thus, mutations of the major acyltransferases Gat1p and Slc1p lead to an increased contribution of mitochondrial acyltransferase(s) to glycerolipid synthesis due to their substrate preference for dihydroxyacetone phosphate.  (+info)

The glycerol phosphate, dihydroxyacetone phosphate and monoacylglycerol pathways of glycerolipid synthesis in rat adipose-tissue homogenates. (3/754)

1. Fat-free homogenates from the epididymal fat-pads of rats were used to measure the rate of palmitate esterification with different substrates. The effectiveness of the acyl acceptors decreased in the order glycerol phosphate, dihydroxyacetone phosphate, 2-octadecenyl-glycerol and 2-hexadecylglycerol. 2. Glycerol phosphate and dihydroxyacetone phosphate inhibited their rates of esterification in a mutually competitive manner. 3. The esterification of glycerol phosphate was also inhibited in a partially competitive manner by 2-octadecenylglycerol and to a lesser extent by 2-hexadecylglycerol. However, glycerol phosphate did not inhibit the esterification of 2-octadecenylglycerol. 4. The esterification of dihydroxyacetone phosphate and 2-hexadecylglycerol was more sensitive to inhibition by clofenapate than was that of glycerol phosphate. Norfenfluramine was more effective in inhibiting the esterification of 2-hexadecylglycerol than that of glycerol phosphate or dihydroxyacetone phosphate. 5 It is concluded that rat adipose tissue can synthesize glycerolipids by three independent routes.  (+info)

The effects of diet on the esterification of glycerol phosphate, dihydroxyacetone phosphate and 2-hexadecylglycerol by homogenates of rat adipose tissue. (4/754)

1. Male rats were fed for 5 weeks after weaning on a diet containing (by weight) 59% of starch or on diets that contained 39% of starch and 20% of either sucrose, beef tallow or corn oil. 2. The rats fed on the beef tallow consumed more energy than did the rats fed on the starch and sucrose diets. The rats fed on the corn oil drank less water than did the other groups of rats. 3. There were no significant differences between the four groups in terms of body-weight gain, epididymal-fat-pad weight and in the size, number and triacylglycerol content of the adipocytes in the fat-pads. 4. There was a significant correlation (P less than 0.001) between the activities of glycerol phosphate acyltransferase and monoacylglycerol acyltransferase in individual rats. Both of these activities were highest in the group fed on the high-starch diet and both correlated with the consumption of glucose by individual rats in the four groups. 5. The percentage of glycerol phosphate converted into diacylglycerol and triacylglycerol was positively correlated with the mean diameters, surface area and triacylglycerol content of the adipocytes for individual rats and was greates in the sucrose-fed rats. 6. The specific activity of dihydroxyacetone phosphate acyltransferase was highest in the rats fed on beef tallow. This activity was positively correlated with the energy intake for all dietary groups over the 5-week feeding period. 7. The results are discussed in terms of the functions of the three routes of glycerolipid synthesis in adipose tissue.  (+info)

Photosystem II regulation of macromolecule synthesis in the blue-green alga Aphanocapsa 6714. (5/754)

Polymers synthesized by heterotrophically growing (glucose as carbon source) cultures of Aphanocapsa 6714 were compared with polymers synthesized in photosynthetically grown cultures. Loss of photosystem II by dark incubation, or inhibition of light-grown cells with the photosystem II-specific inhibitor dichlorophenylmethylurea, caused an 80 to 90% reduction in the rate of lipid and total ribonucleic acid synthesis, and more than a 90% reduction in the rate of protein synthesis. In contrast, glycogen synthesis was reduced only about 50% in dark cells and less than 30% in dichlorphenylmethylurea-inhibited cells. After longer heterotrophic growth, glycogen became the major component, whereas in photosynthetically grown cultures protein was the major constituent. 14C (from 14CO2 and/or [14C]glucose) assimilated into protein by heterotrophically grown cells was found in amino acids in nearly the same proportions as in photosynthetically grown cells. Thus, routes of biosynthesis available to autotropic cells were also available to heterotrophic cultures, but the supply of carbon precursors to those pathways was greatly reduced. The limited biosynthesis in heterotrophic cells was not due to a limitation for cellular energy. The adenylates were maintained at nearly the same concentrations (and hence the energy charge also) as in photosynthetic cells. The concentration of reduced nicotinamide adenine dinucleotide phosphate was higher in heterotrophic (dark) cells than in photosynthetic cells. From rates of CO2 fixation and/or glycogen biosynthesis it was determined that stationary-phase cells expended approximately 835, 165, and less than 42 nmol of adenosine 5'-triphosphate per mg (dry weight) of algae per 30 min during photosynthetic, photoheterotrophic, and chemoheterotrophic metabolism, respectively. Analysis of the soluble metabolite pools in dark heterotrophic cultures by double-labeling experiments revealed rapid equilibration of 14C through the monophosphate pools, but much slower movement of label into the diphosphate pools of fructose-1,6-diphosphate and sedoheptulose-1,7-diphosphate. Carbon did flow into 3-phosphoglycerate in the dark; however, the initial rate was low and the concentration of this metabolite soon fell to an undetectable level. In photosynthetic cells, 14C quickly equilibrated throughout all the intermediates of the reductive pentose cycle, in particular, into 3-phosphoglycerate. Analysis of glucose-6-phosphate dehydrogenase in cell extracts showed that the enzyme was very sensitive to product inhibition by reduced nicotinamide adenine dinucleotide.  (+info)

Randomized trial of calcium glycerophosphate-supplemented infant formula to prevent lead absorption. (6/754)

BACKGROUND: Although additional dietary calcium is recommended frequently to reduce the risk of lead poisoning, its role in preventing lead absorption has not been evaluated clinically. OBJECTIVE: The objective was to determine the safety and to estimate the size of the effect of calcium- and phosphorus-supplemented infant formula in preventing lead absorption. DESIGN: One hundred three infants aged 3.5-6 mo were randomly assigned to receive iron-fortified infant formula (465 mg Ca and 317 mg P/L) or the same formula with added calcium glycerophosphate (1800 mg Ca and 1390 mg P/L) for 9 mo. RESULTS: There was no significant difference between groups in the mean ratio of urinary calcium to creatinine, serum calcium and phosphorus, or change in iron status (serum ferritin, total iron binding capacity). At month 4, the median (+/-SD) increase from baseline in blood lead concentration for the supplemented group was 57% of the increase for the control group (0.04 +/- 0.09 compared with 0.07 +/- 0.10 micromol/L; P = 0.039). This effect was attenuated during the latter half of the trial, with an overall median increase in blood lead concentration from baseline to month 9 of 0.12 +/- 0.13 micromol/L for the control group and 0.10 +/- 0.18 micromol/L for the supplemented group (P = 0.284). CONCLUSIONS: Supplementation did not have a measurable effect on urinary calcium excretion, calcium homeostasis, or iron status. The significant effect on blood lead concentrations during the first 4 mo was in the direction expected; however, because this was not sustained throughout the 9-mo period we cannot conclude that the calcium glycerophosphate supplement prevented lead absorption in this population.  (+info)

Magnetic resonance detects metabolic changes associated with chemotherapy-induced apoptosis. (7/754)

Apoptosis was induced by treating L1210 leukaemia cells with mechlorethamine, and SW620 colorectal cells with doxorubicin. The onset and progression of apoptosis were monitored by assessing caspase activation, mitochondrial transmembrane potential, phosphatidylserine externalization, DNA fragmentation and cell morphology. In parallel, 31P magnetic resonance (MR) spectra of cell extracts were recorded. In L1210 cells, caspase activation was detected at 4 h. By 3 h, the MR spectra showed a steady decrease in NTP and NAD, and a significant build-up of fructose 1,6-bisphosphate (F-1,6-P) dihydroxyacetonephosphate and glycerol-3-phosphate, indicating modulation of glycolysis. Treatment with iodoacetate also induced a build-up of F-1,6-P, while preincubation with two poly(ADP-ribose) polymerase inhibitors, 3-aminobenzamide and nicotinamide, prevented the drop in NAD and the build-up of glycolytic intermediates. This suggested that our results were due to inhibition of glyceraldehyde-3-phosphate dehydrogenase, possibly as a consequence of NAD depletion following poly(ADP-ribose) polymerase activation. Doxorubicin treatment of the adherent SW620 cells caused cells committed to apoptosis to detach. F-1,6-P was observed in detached cells, but not in treated cells that remained attached. This indicated that our observations were not cell line- or treatment-specific, but were correlated with the appearance of apoptotic cells following drug treatment. The 31P MR spectrum of tumours responding to chemotherapy could be modulated by similar effects.  (+info)

Structural equivalents of latency for lysosome hydrolases. (8/754)

1. Structure-linked latency, a trait for most lysosome hydrolase activities, is customarily ascribed to the permeability-barrier function performed by the particle-limiting membrane, which shields enzyme sites from externally added substrates. 2. The influence of various substrate concentrations on the reaction rate has been measured for both free (non-latent) and total (completely unmasked by Triton X-100) hydrolase activities in rat liver cell-free preparations. The substrates were: beta-glycerophosphate, phenolphthalein mono-beta-glucuronide. p-nitrophenyl N-acetyl-beta-D-glucosaminide and p-nitrophenyl beta-D-galactopyranoside. The ratio (free activity/total activity) X 100 is called fractional free activity at any given substrate concentration. 3. The fractional free activity of beta-glucuronidase and beta-N-acetylglucosaminidase were clearly independent of substrate concentration, over the range examined, in both homogenates and lysosome-rich fractions. The fractional free activity of acid phosphatase appeared to be either unaffected (homogenate) or even depressed (lysosome-rich fraction) by increasing the beta-glycerophosphate concentration. The fractional free activity of beta-galactosidase consistently showed a non-linear increase with increasing substrate concentration in both homogenates and lysosome-rich fractions. 4. Procedures such as treatment with digitonin, hypo-osmotic shock and acid autolysis, although effective in causing varying degrees of resolution of the latency of lysosome hydrolase activities, were unable to modify appreciably the pattern of dependence or independence of their fractional free activities on substrate concentration, as compared with that exhibited by control preparations. Ouabain did not affect the free beta-N-acetylglucosaminidase activity of liver homogenates at all. 5. Preincubation of control preparations with beta-glycerophosphate or p-nitrophenyl beta-galactoside did not result in any significant stimulation of the free hydrolytic activity toward these substrates. 6. The results consistently support the view that the membrane of "intact" lysosomes is virtually impermeable to all the substrates tested, except for p-nitrophenyl beta-galactoside, for which the evidence is contradictory. Moreover the progressive unmasking of the hydrolase activities produced by these procedures in vitro reflects the increasing proportion of enzyme sites that are fully accessible to their substrates rather than a graded increase in the permeability of the lysosomal membrane.  (+info)

Glycerophosphates are esters of glycerol and phosphoric acid. In the context of biochemistry and medicine, glycerophosphates often refer to glycerol 3-phosphate (also known as glyceraldehyde 3-phosphate or glycerone phosphate) and its derivatives.

Glycerol 3-phosphate plays a crucial role in cellular metabolism, particularly in the process of energy production and storage. It is an important intermediate in both glycolysis (the breakdown of glucose to produce energy) and gluconeogenesis (the synthesis of glucose from non-carbohydrate precursors).

In addition, glycerophosphates are also involved in the formation of phospholipids, a major component of cell membranes. The esterification of glycerol 3-phosphate with fatty acids leads to the synthesis of phosphatidic acid, which is a key intermediate in the biosynthesis of other phospholipids.

Abnormalities in glycerophosphate metabolism have been implicated in various diseases, including metabolic disorders and neurological conditions.

... is an organic phosphate salt. It was approved for medical use in Australia in November 2019. It is an ... Sodium glycerophosphate, sold under the brand name Glycophos, is a medication used to supplement phosphate. It is administered ... "Summary for ARTG Entry:312021 Glycophos sodium glycerophosphate (as hydrate) 4.32 g/20 mL concentrated solution for injection ... ISBN 3-540-05123-6. "Australian Public Assessment Report for Sodium glycerophosphate (as hydrate)" (PDF). Therapeutic Goods ...
"Showing Compound Calcium glycerophosphate (FDB009054) - FooDB". "Calcium glycerophosphate". www.drugbank.ca. v t e (Articles ... Calcium glycerylphosphate (or calcium glycerophosphate) is a mineral supplement. Formerly it was sold as a nerve tonic. It is ...
It is found that the L-3-glycerophosphate does not enter the mitochondrial matrix, unlike pyruvate. This helps locate the L-3- ... Baranowski T (1963). "α-Glycerophosphate dehydrogenase". In Boyer PD, Lardy H, Myrbäck K (eds.). The Enzymes (2nd ed.). New ... O'Brien SJ, MacIntyre RJ (Oct 1972). "The -glycerophosphate cycle in Drosophila melanogaster. I. Biochemical and developmental ... Brosemer RW, Kuhn RW (May 1969). "Comparative structural properties of honeybee and rabbit alpha-glycerophosphate ...
Chang YY, Kennedy EP (1967). "Phosphatidyl glycerophosphate phosphatase". J. Lipid Res. 8 (5): 456-62. PMID 4292860. Portal: ...
L-alpha-glycerophosphate dehydrogenase, L-glycerol phosphate dehydrogenase, L-glycerophosphate dehydrogenase, NAD+-alpha- ... Other names in common use include alpha-glycerol phosphate dehydrogenase (NAD+), alpha-glycerophosphate dehydrogenase (NAD+), ... Brosemer RW, Kuhn RW (1969). "Comparative structural properties of honeybee and rabbit alpha-glycerophosphate dehydrogenases". ... O'Brien SJ, MacIntyre RJ (1972). "The -glycerophosphate cycle in Drosophila melanogaster. I Biochemical and developmental ...
Ying-Ying Chang and Eugene P. Kennedy (September 1967). "Biosynthesis of phosphatidyl glycerophosphate in Escherichia coli". ...
Boxer GE, Shonk CE (January 1960). "Low levels of soluble DPN-linked alpha glycerophosphate dehydrogenase in tumors". Cancer ... Ohkawa KI, Vogt MT, Farber E (May 1969). "Unusually high mitochondrial alpha glycerophosphate dehydrogenase activity in rat ... Estabrook RW, Sacktor B (October 1958). "alpha-Glycerophosphate oxidase of flight muscle mitochondria". The Journal of ...
"Analysis of glycerophosphate- and sphingolipids by CE". Electrophoresis. 35 (6): 779-792. doi:10.1002/elps.201300534. PMID ...
Ringler RL (April 1961). "Studies on the mitochondrial alpha-glycerophosphate dehydrogenase. II. Extraction and partial ...
June 2014). "Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase". Nature. 510 ( ...
L-alpha-glycerophosphate oxidase, alpha-glycerophosphate oxidase, and L-alpha-glycerol-3-phosphate oxidase. This enzyme ... Koditschek LK, Umbreit WW (1969). "Alpha-glycerophosphate oxidase in Streptococcus faecium F 24". J. Bacteriol. 98 (3): 1063-8 ...
Koditschek, L. K.; Umbreit, W. W. (1969). "Α-Glycerophosphate Oxidase in Streptococcus faecium F 24". Journal of Bacteriology. ...
β-Glycerophosphate is also used to drive osteogenic differentiation of bone marrow stem cells in vitro. β-Glycerophosphate is ... β-Glycerophosphate is an inhibitor of the enzyme serine-threonine phosphatase. It is often used in combination with other ... It is commonly known as β-glycerophosphate or BGP. Unlike glycerol 1-phosphate and glycerol 3-phosphate, this isomer is not ... "β-Glycerophosphate disodium salt hydrate". Sigma-Aldrich. Retrieved 2018-05-30. "Protease and Phosphatase Inhibitors". Thermo ...
Mutations that inactivate the nonessential glycerophosphate transporter render bacteria resistant to fosfomycin. Prescribing ... Fosfomycin enters the bacterial cell through the glycerophosphate transporter. Fosfomycin (originally known as phosphonomycin) ...
Cozzarelli, Nicholas Robert (1996). The L-L-Glycerophosphate Regulon in Escherichia coli (PhD thesis). Harvard University. OCLC ...
Other names in common use include alpha-glycerophosphate acyltransferase, 3-glycerophosphate acyltransferase, ACP:sn-glycerol-3 ... glycerophosphate acyltransferase, glycerophosphate transacylase, sn-glycerol 3-phosphate acyltransferase, and sn-glycerol-3- ... Yamashita S, Numa S (1972). "Partial purification and properties of glycerophosphate acyltransferase from rat liver. Formation ...
Other names in common use include D-2-phosphoglycerate phosphatase, and glycerophosphate phosphatase. Fallon HJ, Byrne WL (1965 ...
... glycerophosphate)n+1 Thus, the two substrates of this enzyme are CDP-glycerol and (glycerophosphate)n, whereas its two products ... The systematic name of this enzyme class is CDP-glycerol:poly(glycerophosphate) glycerophosphotransferase. Other names in ... glycerophosphate synthetase, and CGPTase. BURGER MM, GLASER L (1964). "THE SYNTHESIS OF TEICHOIC ACIDS. I. POLYGLYCEROPHOSPHATE ... are CMP and (glycerophosphate)n+1. This enzyme belongs to the family of transferases, specifically those transferring non- ...
... and glycerophosphate, as a tonic, strengthener. Marketed also as an aphrodisiac. Penicilline-Hamma: Penicillin - powder Topical ...
Other names in common use include β-glycerophosphatase, β-glycerophosphate phosphatase, and 2-glycerophosphatase. Boyer, P.D., ...
S. barbata was used to study the oxidation of L-3-glycerophosphate in mitochondria. It is found that the L-3-glycerophosphate ... S. barbata is also a prominent organism in scientific research and has been used to study L-3-glycerophosphate oxidation and ... Donnellan JF, Barker MD, Wood J, Beechey RB (December 1970). "Specificity and locale of the L-3-glycerophosphate-flavoprotein ... This helps locate the L-3-glycerophosphate-flavoprotein oxidoreductase, which is on the inner membrane of the mitochondria. ...
Sensitivity to trigger foods may be reduced if calcium glycerophosphate and/or sodium bicarbonate is consumed. The foundation ...
Another thermo-responsive gel is one that is formed by combining chitosan with glycerophosphate (GP) salt. This solution ...
Rahmanian-Devin, Pouria; Baradaran Rahimi, Vafa; Askari, Vahid Reza (2021). "Thermosensitive Chitosan-β-Glycerophosphate ...
It was originally called M16 medium, but in 1975 Terzaghi and Sandine added disodium-β-glycerophosphate to the medium as a ... It was later found that the addition of disodium-β-glycerophosphate inhibits the growth of many Lactobacillus species. Per 950 ... Shankar PA, Davies FL (1977). "A note on the suppression of Lactobacillus bulgaricus in media containing β-glycerophosphate and ... Peptone 5.0 g Beef extract 2.5 g Yeast extract 0.5 g Ascorbic acid 0.25 g Magnesium sulfate 19.0 g Disodium-β-glycerophosphate ...
Both versions of the drink contain phosphate and glycerophosphate, each of these as the sodium and/or potassium salt. The " ...
... glycerophosphate) backbones". Journal of Bacteriology. 189 (11): 4135-40. doi:10.1128/JB.00078-07. PMC 1913418. PMID 17416656. ...
... key enzyme in biosynthesis of the enantiomeric glycerophosphate backbone of ether phospholipids of archaebacteria". J. Biochem ...
"Identification and functional analysis of mutations in FAD-binding domain of mitochondrial glycerophosphate dehydrogenase in ...
A hypothesis stating that the advent of membrane phospholipid with enantiomeric glycerophosphate backbones caused the ...
Sodium glycerophosphate is an organic phosphate salt. It was approved for medical use in Australia in November 2019. It is an ... Sodium glycerophosphate, sold under the brand name Glycophos, is a medication used to supplement phosphate. It is administered ... "Summary for ARTG Entry:312021 Glycophos sodium glycerophosphate (as hydrate) 4.32 g/20 mL concentrated solution for injection ... ISBN 3-540-05123-6. "Australian Public Assessment Report for Sodium glycerophosphate (as hydrate)" (PDF). Therapeutic Goods ...
Hazard - P - B - T - Risk Exempt. According to the European Medicines Agency guideline on environmental risk assessments for pharmaceuticals (EMA/CHMP/SWP/4447/00) vitamins, electrolytes, amino acids, peptides, proteins, carbohydrates, lipids proteins, vaccines and herbal medicinal products are exempted because they are unlikely to result in significant risk to the environment. ...
... off Calcium Glycerophosphate at the pharmacy. Coupons, discounts, and promos updated 2021. ... Get Calcium Glycerophosphate Coupon Card by print, email or text and save up to 48% ... Calcium Glycerophosphate Coupon & Discounts. Save on Calcium Glycerophosphate at your pharmacy with the free discount below. ... Claim your free Calcium Glycerophosphate discount. *. Click the Get free coupon button to receive your free Calcium ...
... with chitosan/β-glycerophosphate/collagen(C/GP/Co) hydrogel promotes healing after an acute Achilles tendon injury in a rat ... Effect of Tendon Stem Cells in Chitosan/β-Glycerophosphate/Collagen Hydrogel on Achilles Tendon Healing in a Rat Model DOI: ...
"Glycerophosphates" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical Subject ... This graph shows the total number of publications written about "Glycerophosphates" by people in this website by year, and ... Below are the most recent publications written about "Glycerophosphates" by people in Profiles. ... whether "Glycerophosphates" was a major or minor topic of these publications. To see the data from this visualization as text, ...
Copper Glycerophosphate Manufacturers Suppliers, SDS MSDS Sheet, Exporters to USA Canada Egypt Turkey UAE ... Copper Glycerophosphate Manufacturers, with SDS GHS MSDS Sheet. Supplier, Manufacturer, Exporter of Copper Glycerophosphate ... Product Name & Other Names: Copper Glycerophosphate.. CAS Number: 85187-41-3. EINECS EC Code: 286-131-6. Chemical Formula: ... Copper Glycerophosphate: CAS Number: 85187-41-3, EINECS EC Number: 286-131-6, Molecular Formula: C3H7CuO6P-xH2O, Molecular ...
Be the first to review "Magnevite organic magnesium glycerophosphate". You must be logged in to post a review. ...
glycerophosphate oxidase. Glycerol-3-phosphate + O2--------------------------------, dihydroxyacetone phosphate + H2O2 ...
Thermosensitive hydrogel made of ferulic acid-gelatin and chitosan glycerophosphate. Yung Hsin Cheng, Shu Hua Yang, Chia Ching ... Thermosensitive hydrogel made of ferulic acid-gelatin and chitosan glycerophosphate. / Cheng, Yung Hsin; Yang, Shu Hua; Liu, ... Thermosensitive hydrogel made of ferulic acid-gelatin and chitosan glycerophosphate. Carbohydrate Polymers. 2013 Feb 15;92(2): ... Thermosensitive hydrogel made of ferulic acid-gelatin and chitosan glycerophosphate. In: Carbohydrate Polymers. 2013 ; Vol. 92 ...
2005-2021 Solarbio all rights reserved. ICP Filing Certificate No:京ICP备12051307号-7 ...
magnesium glycerophosphate. magnesium salts of orthophosphoric acid. magnesium lactate. magnesium L-lysinate ...
Choline glycerophosphate ChemIDplus Cholini glycerophosphas ChemIDplus Glicerofosfato de colina ChemIDplus Glycerol ...
The C/GP/Co hydrogel is prepared by mixing 2.2% (v/v) chitosan with 50% (w/w) β-glycerophosphate at different proportions and ... This paper introduces a novel type of injectable temperature-sensitive chitosan/glycerophosphate/collagen (C/GP/Co) hydrogel ... The C/GP/Co hydrogel is prepared by mixing 2.2% (v/v) chitosan with 50% (w/w) β-glycerophosphate at different proportions and ... This paper introduces a novel type of injectable temperature-sensitive chitosan/glycerophosphate/collagen (C/GP/Co) hydrogel ...
We conclude that sodium glycerophosphate, when added to parenteral nutrition formulations together with calcium gluconate in ... A sterile and apyrogenic sodium glycerophosphate solution for intravenous administration, not commercially available in Brazil ... were prepared by adding 4 mmol/dL phosphorus and 3.712 mmol/dL calcium using as sources solutions of 1 mmol/mL glycerophosphate ... between calcium and phosphorus in parenteral nutrition formulations using calcium gluconate and sodium glycerophosphate ...
STRAIN PMF SOAKED WITH THE PRODUCT GLYCEROPHOSPHATE. Coordinates. PDB Format Method. X-RAY DIFFRACTION 1.42 Å. Oligo State. ... STRAIN PMF SOAKED WITH THE PRODUCT GLYCEROPHOSPHATE. ...
Potassium Glycerophosphate Boiling Point: 485.50 A C 760.00 Mm Hg. Price: 600 INR (Approx.) ...
Among these suppressors, Glycerophosphate oxidase-1 is found to participate in debcl-induced apoptosis by increasing ... Among these suppressors, Glycerophosphate oxidase-1 is found to participate in debcl-induced apoptosis by increasing ... Screening of suppressors of bax-induced cell death identifies glycerophosphate oxidase-1 as a mediator of debcl-induced ... Screening of suppressors of bax-induced cell death identifies glycerophosphate oxidase-1 as a mediator of debcl-induced ...
glycerophosphate, and one of the commercial inhibitors. A follow-up study is under way to allow: (a) additional testing of ...
DAO_C; C-terminal domain of alpha-glycerophosphate oxidase. Related sequences Go to the top of the page Help ...
Calcium Glycerophosphate, L-Carnitine Tartrate, Corn Oil, Natural Source Colour (Mixed Carotenes [Polysorbate 80, Sunflower Oil ...
Belongs to the class of organic compounds known as glycerophosphates. Glycerophosphates are compounds containing a glycerol ...
Categories: Glycerophosphates Image Types: Photo, Illustrations, Video, Color, Black&White, PublicDomain, CopyrightRestricted 4 ...
This study aims to investigate the effectivity and safety of a new crystalloid solution by adding sodium glycerophosphate to a ... trial involving two parallel groups of female patients comparing a perioperative infusion regime with sodium glycerophosphate ... Sodium glycerophosphate. Sodium glycerophosphate (Fresenius Kabi AG, Bad Homburg, Germany; concentration 1 mmol/ml, ATC-Code: ... By administering sodium glycerophosphate pre-emptively, it is hypothesized that stable values of [A−] can be maintained in ...
Fischer, W., Mannsfeld, T., and Hagen, G. (1990). On the basic structure of poly (glycerophosphate) lipoteichoic acids. Biochem ...
2014). Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510, 542-546. ...
Potassium (as citrate and glycerophosphate). 20mg. 0. B-NOX Pre-Workout Formula. 15845mg. †. ...
Bleier BS, Paulson DP, OMalley BW Jr, Li D, Palmer JN, Chiu AG, Cohen NA: Chitosan glycerophosphate-based semirigid ...
Sodium Glycerophosphate. * Selaginella Lepidophylla Extract. * Potassium Magnesium Aspartate. * Citric Acid. * Calcium ...
Calcium Glycerophosphate, Sodium Citrate, Zinc Gluconate, Potassium Phosphate, Sodium Ascorbyl Phosphate, Benzoic Acid, Sodium ...
  • Sodium glycerophosphate, sold under the brand name Glycophos, is a medication used to supplement phosphate. (wikipedia.org)
  • Sodium glycerophosphate is an organic phosphate salt. (wikipedia.org)
  • Australian Public Assessment Report for Sodium glycerophosphate (as hydrate)" (PDF). (wikipedia.org)
  • A sterile and apyrogenic sodium glycerophosphate solution for intravenous administration, not commercially available in Brazil, was developed and added to standard parenteral nutrition formulations used at the University Hospital, Faculty of Medicine of Ribeirão Preto, University of São Paulo, in order to supply phosphorus together with calcium. (usp.br)
  • We conclude that sodium glycerophosphate, when added to parenteral nutrition formulations together with calcium gluconate in the amounts and under the conditions tested here did not present in vitro incompatibility. (usp.br)
  • This is a single-centre, open-label, randomized controlled trial involving two parallel groups of female patients comparing a perioperative infusion regime with sodium glycerophosphate and Jonosteril® (treatment group) or Jonosteril® (comparator) alone. (biomedcentral.com)
  • This study aims to investigate the effectivity and safety of a new crystalloid solution by adding sodium glycerophosphate to a standardized crystalloid preparation in order to maintain a balanced perioperative acid-base homeostasis. (biomedcentral.com)
  • Evaluating thermosensitive chitosan/ β-glycerophosphate sodium and fibroblast embolization for the treatment of cerebral arteriovenous malformation in a porcine model. (nel.edu)
  • To evaluate the feasibility of non-sticky thermosensitive liquid embolic material chitosan/β-glycerophosphate sodium (C/GP) an. (nel.edu)
  • Ning X, Zhao C, Zhao J, Pang J. Evaluating thermosensitive chitosan/ β-glycerophosphate sodium and fibroblast embolization for the treatment of cerebral arteriovenous malformation in a porcine model. (nel.edu)
  • Sanatogen Trade name for a preparation of casein and sodium glycerophosphate for consumption as a beverage when added to milk. (encyclopedia.com)
  • Sodium glycerophosphate increases the buffering capacity of the medium, this promotes the growth of lactic streptococci and inhibits lactobacilli growth. (sigmaaldrich.com)
  • Preparation, fabrication and biocompatibility of novel injectable temperature-sensitive chitosan/glycerophosphate/collagen hydrogels. (ox.ac.uk)
  • This paper introduces a novel type of injectable temperature-sensitive chitosan/glycerophosphate/collagen (C/GP/Co) hydrogel that possesses great biocompatibility for the culture of adipose tissue-derived stem cells. (ox.ac.uk)
  • Pantothenic Acid (Calcium Pantothenate), Magnesium Glycerophosphate, Capsule Shell (Hydroxypropyl Methylcellulose), Anti-Caking Agents (Magnesium Stearate & Silicon Dioxide). (health4youonline.com)
  • The C/GP/Co hydrogel is prepared by mixing 2.2% (v/v) chitosan with 50% (w/w) β-glycerophosphate at different proportions and afterwards adding 2 mg/ml of collagen. (ox.ac.uk)
  • These parenteral nutrition formulations were prepared by adding 4 mmol/dL phosphorus and 3.712 mmol/dL calcium using as sources solutions of 1 mmol/mL glycerophosphate and 10% calcium gluconate (w/v) and kept at a temperature (5 + 3oC) for 0, 6, 12 and 24 hours, followed by 24 hours at room temperature of 24 + 3oC. (usp.br)
  • Supplier, Manufacturer, Exporter of Copper Glycerophosphate Muby Chemicals of Mubychem Group, established in 1976, is the original manufacturers of Specialty Chemicals, Pharmaceutical Excipient, Fragrance Food & Flavor chemicals, Reagent Grade Chemicals, Shale Gas Fracturing Chemicals in India. (mubychem.com)
  • Magnesium glycerophosphate is a magnesium salt that is available as a tablet, capsule, liquid solution or liquid suspension for oral use. (nice.org.uk)
  • The British national formulary (BNF) states that oral magnesium glycerophosphate is a suitable preparation to prevent recurrence of symptomatic hypomagnesaemia in people who have already been treated for this condition. (nice.org.uk)
  • This evidence summary looks at the use of oral magnesium glycerophosphate in patients who have previously been treated with an intravenous infusion of magnesium. (nice.org.uk)
  • Oral magnesium glycerophosphate does not have UK marketing authorisation for this or any other indication, and therefore it is an unlicensed medicine in the UK. (nice.org.uk)
  • No published clinical trials comparing the efficacy of oral magnesium glycerophosphate with placebo or any form of active treatment for preventing recurrent hypomagnesaemia after treatment with intravenous magnesium were identified. (nice.org.uk)
  • The only evidence found was from 3 case reports describing the use of oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia in adults after intravenous treatment. (nice.org.uk)
  • In both these patients, oral magnesium glycerophosphate was not sufficient to maintain serum magnesium levels after initial intravenous treatment. (nice.org.uk)
  • In 1 patient, switching from oral magnesium glycerophosphate to oral magnesium oxide resulted in maintenance of serum magnesium levels, but in the other patient this was still not sufficient and intravenous magnesium top ups were needed every 3-6 months. (nice.org.uk)
  • In this patient, magnesium levels remained low after oral supplementation with magnesium glycerophosphate but reverted to normal after the proton pump inhibitor was discontinued, even after the magnesium supplement was stopped. (nice.org.uk)
  • No studies of oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia in children after intravenous treatment were identified. (nice.org.uk)
  • Potassium Glycerophosphate is often used together with sodium Glycerophosphate, Magnesium Glycerophosphate, calcium Glycerophosphate in sports nutrition formulas as electrolytes to supply a large amount of mineral elements such as sodium, calcium, magnesium etc needed for muscle performance and bone & joint health. (cimasci.com)
  • The Glycovascularity Proprietary Blend contains 200mg of Potassium Glycerophosphate and Magnesium Glycerophosphate per capsule. (cimasci.com)
  • In the EVP Xtreme Electrolyte Matrix (5.2g) Blend, Potassium Glycerophosphate is 525mg, Sodium Glycerophosphate is 788mg, and Magnesium Glycerophosphate is 525mg. (cimasci.com)
  • Potassium Glycerophosphate, together with calcium Glycerophosphate, Magnesium Glycerophosphate, and other Glycerophosphate salts are popular among supplement brands. (cimasci.com)
  • High-bioavailability and high-absorption magnesium glycerophosphate chelate is the newest form of magnesium that brings everything you want. (priceplow.com)
  • Of the substrates, only the increase in alpha-glycerophosphate in the high dose rats was significant. (cdc.gov)
  • Recent advances demonstrate that metformin could exert its glucose-lowering effect by multiple mechanisms, including activation of 5′-AMP-activated protein kinase, decreasing production of cyclic AMP, suppressing mitochondrial complex I of the electron transport chain, targeting glycerophosphate dehydrogenase, and altering the gut microbiome. (frontiersin.org)
  • We found that mitochondrial glycerophosphate dehydrogenase (mGPDH) is one of the metformin targets in thyroid cancer. (nih.gov)
  • Potassium Glycerophosphate is a mineral ingredient and is always added as a non-key ingredient in many bodybuilding supplements. (cimasci.com)
  • You'll notice that sports nutrition brands prefer to use Potassium Glycerophosphate than any other dietary supplement formulas. (cimasci.com)
  • According to the Code of Federal Regulations Title 21, SUBCHAPTER E-ANIMAL DRUGS, FEEDS, AND RELATED PRODUCTS, DEPARTMENT OF HEALTH AND HUMAN SERVICES, Potassium glycerophosphate is generally recognized as safe when used in accordance with good manufacturing or feeding practice. (cimasci.com)
  • Potassium Glycerophosphate is a Glycerophosphate salt combined with the trace element of Potassium. (cimasci.com)
  • These glycerophosphate-based phospholipids are found in many biological membranes as head-group modified phospholipids including PG, cardiolipin, PE, PS, and PA. (avantilipids.com)
  • The GlyceroPump is 3000mg per serving size, but we don't know the exact amount of Potassium Glycerophosphate in it. (cimasci.com)
  • The amount of Potassium Glycerophosphate per serving is 315mg per day. (cimasci.com)
  • These complex lipids are composed of fatty acids bound to glycerophosphate or sphingosine. (enterrasolutions.com)
  • A 40% Optiprep (Sigma: D1556), 20mM Beta-glycerophosphate pH7, 2mM EDTA and 0.5% NP40 solution was then carefully placed under each aliquot. (nih.gov)